Barrett食管腺癌及其癌前病变中AgNOR和PCNA的表达及临床意义

EXPRESSION AND CLINICAL SIGNIFICANCE OF THE AGNOR AND PCNA IN BARRETT'S ADENOCARCINOMA AND ITS PRECANCEROUS LESIONS

为探讨细胞核仁形成区相关嗜银蛋白（ＡｇＮＯＲ）和增殖细胞核抗原（ＰＣＮＡ）在Ｂａｒｒｅｔｔ食管腺癌及其癌前病变中的表达，对５０例患者的食管标本进行了银染色和免疫组化染色。结果表明，恶性组ＡｇＮＯＲ和ＰＣＮＡ的表达明显高于癌前病变组和良性组，其表达依次呈递减趋势，各组间比较差异均有显著性意义。结果提示，ＡｇＮＯＲ和ＰＣＮＡ的表达异常可做为临床判别良恶性Ｂａｒｒｅｔｔ食管的指标之一，有助于对高危人群进行监测并早期发现Ｂａｒｒｅｔｔ食管恶性变。

AbstractIn order to investigate the expression of AgNOR and PCNA in malignant Barrett's esophagusand benign Barrett's esophagus with or without dysplasia, 50 specimens and biopsies were examinedusing silver-staining and immunohistochemical methods.The results showed that the expression ofAgNOR and PCNA in malignant Barrett's esophagus were higher than those in benign Barrett'sesophagus with dysplasia , which were in turn higher than those in benign Barrett's esophagus withoutdysplasia. The difference between malignant group and other groups was significant. The results sug-gest that AgNOR and PCNA may be useful as an adjunct in screening patients with Barrett's esopha-gus for early malignant change, especially in high-grade dysplasia group.